Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Classification of Illness01:17

Classification of Illness

The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study.

The American journal of gastroenterology·2026
Same author

Faecalibacterium prausnitzii EXL01 for the Maintenance of Steroid-induced Clinical Response or Remission in Patients with Crohn's Disease: a first in human trial.

Nature communications·2026
Same author

Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.

Crohn's & colitis 360·2026
Same author

Effects of prehabilitation programmes on postoperative outcomes in older adults undergoing major abdominal, cardiac or vascular surgery: a systematic review.

Aging clinical and experimental research·2026
Same journal

Trembling technique for improving colonic adenoma detection rate by enhancing mucosal exposure during withdrawal: A prospective, non-randomized single center study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Consensus recommendations for the management of H. pylori in Egypt: 2026 report.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Deep remission: a new concept?

Jean-Frédéric Colombel1, Edouard Louis, Laurent Peyrin-Biroulet

  • 1Department of Hepatogastroenterology, CHU Lille, Université Lille Nord de France, Lille, France. jean-frederic.colombel @ chru-lille.fr

Digestive Diseases (Basel, Switzerland)
|January 9, 2013
PubMed
Summary
This summary is machine-generated.

A new treatment goal, sustained deep remission, is proposed for Crohn's disease (CD) to prevent disease progression and disability. This strategy aims for long-term symptom control and biological remission, unlike current approaches.

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Experiment Videos

Last Updated: May 15, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Area of Science:

  • Gastroenterology
  • Immunology
  • Clinical Medicine

Background:

  • Crohn's disease (CD) is a chronic, progressive inflammatory disorder leading to significant bowel damage, complications, and disability.
  • Current CD management focuses on symptom control but lacks a comprehensive goal for both clinical and biological remission.
  • The 'treat to target' strategy in rheumatoid arthritis has improved long-term outcomes by aiming for sustained remission.

Purpose of the Study:

  • To propose and define a new treatment concept for Crohn's disease: sustained deep remission.
  • To establish a treatment goal that addresses both clinical symptoms and underlying biologic inflammation in CD.
  • To emphasize the need for strategies that prevent disease progression and disability in Crohn's disease patients.

Main Methods:

  • Literature review and conceptualization of a "sustained deep remission" definition for CD.
  • Comparison with existing treatment paradigms in rheumatoid arthritis and current CD management.
  • Proposal for future clinical trials to validate the efficacy of deep remission-focused treatment algorithms.

Main Results:

  • A working definition of sustained deep remission, incorporating long-term biological remission and symptom control with defined patient outcomes (e.g., no disease progression), has been proposed.
  • The concept of sustained deep remission offers a potential new goal for CD management.
  • The applicability of this concept to ulcerative colitis requires further investigation.

Conclusions:

  • A shift towards a 'treat to target' strategy, aiming for sustained deep remission, is crucial for improving long-term outcomes in Crohn's disease.
  • Achieving sustained deep remission may prevent disease progression, complications, and disability associated with CD.
  • Further clinical trials are necessary to evaluate treatment algorithms designed to achieve deep remission in CD and prevent disease progression.